|[March 25, 2014]
Research and Markets: Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product Launches
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/khf2lr/pharmapoint)
has announced the addition of the "PharmaPoint:
Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and
Market Analysis to 2022" report to their offering.
Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming
The global hepatitis B virus (HBV) vaccine market value will experience
modest growth over the coming years, climbing from approximately $959.9
million in 2012 to $1.19 billion by 2022, at a Compound Annual Growth
Rate (CAGR) of 2.2%.
Out of the eight major markets the US, Canada, France, Germany, Italy,
Spain, the UK and Japan the majority of HBV vaccine sales will take
place in the US, which will boast a higher CAGR of 3.4% and expand its
market share from 55% to 61.7% during the forecast period. The US will
be followed by Canada and the five European countries, with expected
CAGRs of 1% and 0.5%, respectively.
The growth in HBV vaccine sales will result from the launch of Dynavax
Technologies' Heplisav and Sanofi Pasteur MD's Hexyon, with peak-year
sales anticipated to reach $85 million and $520 million, respectively.
Christopher Pace, Ph.D., The report Analyst covering Infectious
Diseases, says: Dynavax hopes to leverage Heplisav's superior
immunogenicity and dosing regimen to increase HBV vaccine uptake in the
adult market. On the other hand, Sanofi Pasteur MSD is positioning
Hexyon to be the first fully liquid pediatric hexavalent vaccine.
However, the authors believe that inadequate HBV vaccination coverage
rates in certain high-risk populations represents one of the most
important unmet needs in the marketplace.
Pace says: In the pediatric segment, companies are leveraging
combination vaccines to increase HBV vaccine uptake, while improved
dosing regimens are necessary to increase vaccination coverage rates in
For both children and adults, these companies must ensure that
physicians understand immunization recommendations and are able to
effectively identify patients. Overall, ensuring high coverage rates
will be essential to the commercial success of HBV vaccines during the
This report provides an overview of hepatitis B virus (HBV), including
etiology, general symptoms from infection, and country-specific
immunization recommendations and vaccination coverage data. It also
gives annualized HBV vaccine market revenue, annual cost of vaccination
and treatment usage pattern data from 2012 to 2022.
Key Topics Covered:
List of Tables
List of Figures
Vaccination Recommendations and Coverage Rates
Opportunity and Unmet Need
Current and Future Players
For more information visit http://www.researchandmarkets.com/research/khf2lr/pharmapoint
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To TMCnet.com's Homepage ]